Mumbai, 21 December 2021:
MSN Pharmaceuticals Inc. (MSNPI), a wholly-owned subsidiary of MSN Group of Companies, based out of Piscataway, New Jersey, USA successfully completed its maiden USFDA audit with zero observations.
The state-of-the-art finished dosages facility was established to bolster MSN Group’s product portfolio as well as Contract Development & Manufacturing services, in the US and several other key regulatory markets.
“This is a major accomplishment for us. It augments the core strategy of establishing ourselves as a preferred Contract Development & Manufacturing Service provider globally, offering end-to-end drug manufacturing services. Also, besides helping us to deepen our presence in the US market, it will enable us to make high-quality generics affordable and accessible to the patients swiftly and efficiently.”MSN Group commented on the occasion.
Backed by novel technologies and innovative R&D expertise, MSN Pharmaceuticals Inc. is well-equipped to deliver complex and high-quality pharmaceutical products in General and DEA Controlled categories. In addition, the world-class production and backward integration capabilities help in efficiently catering to large-scale commercial volumes of Made-In-America Pharmaceutical products.
For more information on MSN Pharmaceuticals Inc., please visit https://www.msnpi.com/
About MSN Group:
MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 16 state-of-the-art manufacturing facilities (twelve API and four finished dosage facilities) established across India and USA. The Group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals. With its core focus on speed and consistency in delivery, MSN has more than 823 national and international patents filed, over 130 ANDAs, and emerged as world no. 1 in active US DMF filings. The company, with a product portfolio of 450+ APIs and 300+ formulations spanning 35 major therapies, has won the trust of more than 40 million patients in 65 countries across the world.
For information on MSN Labs, please visit www.msnlabs.com